Emotional disorders in testicular cancer survivors in relation to hypogonadism, androgen receptor polymorphism and treatment modality

Journal of Affective Disorders

Volumn 122, Issue 3, 2010, Pages 260-266

  Eberhard, Jakob ^a   Ståhl, Olof ^a   Cohn Cedermark, Gabriella ^c   Cavallin Ståhl, Eva ^a   Giwercman, Yvonne ^b   Rastkhani, Hamideh ^b   Rylander, Lars ^b   Eberhard Gran, Malin ^d   Kvist, Ulrik ^c,e   Giwercman, Aleksander ^a,b  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b LUND UNIVERSITY   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^e KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Androgen receptor polymorphism; Anxiety; Depression; Hypogonadism; Testicular cancer

Indexed keywords

ANDROGEN RECEPTOR; CISPLATIN; LUTEINIZING HORMONE; TESTOSTERONE;

ANXIETY; ARTICLE; CANCER RELAPSE; CANCER SURVIVOR; DEPRESSION; EMOTIONAL STRESS; EXON; GENETIC POLYMORPHISM; GERM CELL TUMOR; HOSPITAL ANXIETY AND DEPRESSION SCALE; HUMAN; HYPOGONADISM; LUTEINIZING HORMONE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH; MULTIPLE CYCLE TREATMENT; ORCHIECTOMY; PRIORITY JOURNAL; QUESTIONNAIRE; RECEPTOR GENE; RECURRENT CANCER; RISK ASSESSMENT; TESTOSTERONE BLOOD LEVEL; TRINUCLEOTIDE REPEAT;

ADULT; ANTINEOPLASTIC AGENTS; ANXIETY; CISPLATIN; DEPRESSION; GENETIC PREDISPOSITION TO DISEASE; GERMINOMA; HUMANS; HYPOGONADISM; LUTEINIZING HORMONE; MALE; MOOD DISORDERS; NEOPLASM STAGING; POLYMORPHISM, GENETIC; QUESTIONNAIRES; RECEPTORS, ANDROGEN; RECURRENCE; RISK FACTORS; SURVIVORS; SWEDEN; TESTICULAR NEOPLASMS; TESTOSTERONE; TIME FACTORS;

EID: 77949656645     PISSN: 01650327     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jad.2009.06.035     Document Type: Article

References (30)

1. Agledahl I., Skjaerpe P.A., Hansen J.B., and Svartberg J. Low serum testosterone in men is inversely associated with non-fasting serum triglycerides: the Tromso study. Nutr. Metab. Cardiovasc. Dis. 18 (2008) 256-262
2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4 ed. (1995), American Psychiatric Press, Washington, DC
3. Bjelland I., Dahl A.A., Haug T.T., and Neckelmann D. The validity of the Hospital Anxiety and Depression Scale. An updated literature review. J. Psychosom. Res. 52 (2002) 69-77
4. Carnegie C. Diagnosis of hypogonadism: clinical assessments and laboratory tests. Rev. Urol. 6 Suppl 6 (2004) S3-8
5. Dahl A.A., Haaland C.F., Mykletun A., Bremnes R., Dahl O., Klepp O., Wist E., and Fossa S.D. Study of anxiety disorder and depression in long-term survivors of testicular cancer. J. Clin. Oncol. 23 (2005) 2389-2395
6. Dahl A.A., Mykletun A., and Fossa S.D. Quality of life in survivors of testicular cancer. Urol. Oncol. 23 (2005) 193-200
7. Eberhard J., Stahl O., Giwercman Y., Cwikiel M., Cavallin-Stahl E., Lundin K.B., Flodgren P., and Giwercman A. Impact of therapy and androgen receptor polymorphism on sperm concentration in men treated for testicular germ cell cancer: a longitudinal study. Hum. Reprod. 19 (2004) 1418-1425
8. Eberhard J., Stahl O., Cwikiel M., Cavallin-Stahl E., Giwercman Y., Salmonson E.C., and Giwercman A. Risk factors for post-treatment hypogonadism in testicular cancer patients. Eur. J. Endocrinol. 158 (2008) 561-570
9. Eberhard J., Stahl O., Cohn-Cedermark G., Cavallin-Stahl E., Giwercman Y., Rylander L., Eberhard-Gran M., Kvist U., Fugl-Meyer K.S., and Giwercman A. Sexual function in men treated for testicular cancer. J. Sex. Med. (2009)
10. Fleer J., Hoekstra H.J., Sleijfer D.T., and Hoekstra-Weebers J.E. Quality of life of survivors of testicular germ cell cancer: a review of the literature. Support Care Cancer 12 (2004) 476-486
11. Fossa S.D., Lehne G., Heimdal K., and Theodorsen L. Clinical and biochemical long-term toxicity after postoperative cisplatin-based chemotherapy in patients with low-stage testicular cancer. Oncology 52 (1995) 300-305
12. Fossa S.D., Dahl A.A., and Loge J.H. Fatigue, anxiety, and depression in long-term survivors of testicular cancer. J. Clin. Oncol. 21 (2003) 1249-1254
13. Harkonen K., Huhtaniemi I., Makinen J., Hubler D., Irjala K., Koskenvuo M., Oettel M., Raitakari O., Saad F., and Pollanen P. The polymorphic androgen receptor gene CAG repeat, pituitary-testicular function and andropausal symptoms in ageing men. Int. J. Androl. 26 (2003) 187-194
14. Horwich A., Brada M., Nicholls J., Jay G., Hendry W.F., Dearnaley D., and Peckham M.J. Intensive induction chemotherapy for poor risk non-seminomatous germ cell tumours. Eur. J. Cancer Clin. Oncol. 25 (1989) 177-184
15. Joly F., Heron J.F., Kalusinski L., Bottet P., Brune D., Allouache N., Mace-Lesec'h J., Couette J.E., Peny J., and Henry-Amar M. Quality of life in long-term survivors of testicular cancer: a population-based case-control study. J. Clin. Oncol. 20 (2002) 73-80
16. Katz M.R., Kopek N., Waldron J., Devins G.M., and Tomlinson G. Screening for depression in head and neck cancer. Psychooncology 13 (2004) 269-280
17. Krege S., Beyer J., Souchon R., Albers P., Albrecht W., Algaba F., Bamberg M., Bodrogi I., Bokemeyer C., Cavallin-Stahl E., Classen J., Clemm C., Cohn-Cedermark G., Culine S., Daugaard G., De Mulder P.H., De Santis M., de Wit M., de Wit R., Derigs H.G., Dieckmann K.P., Dieing A., Droz J.P., Fenner M., Fizazi K., Flechon A., Fossa S.D., del Muro X.G., Gauler T., Geczi L., Gerl A., Germa-Lluch J.R., Gillessen S., Hartmann J.T., Hartmann M., Heidenreich A., Hoeltl W., Horwich A., Huddart R., Jewett M., Joffe J., Jones W.G., Kisbenedek L., Klepp O., Kliesch S., Koehrmann K.U., Kollmannsberger C., Kuczyk M., Laguna P., Galvis O.L., Loy V., Mason M.D., Mead G.M., Mueller R., Nichols C., Nicolai N., Oliver T., Ondrus D., Oosterhof G.O., Ares L.P., Pizzocaro G., Pont J., Pottek T., Powles T., Rick O., Rosti G., Salvioni R., Scheiderbauer J., Schmelz H.U., Schmidberger H., Schmoll H.J., Schrader M., Sedlmayer F., Skakkebaek N.E., Sohaib A., Tjulandin S., Warde P., Weinknecht S., Weissbach L., Wittekind C., Winter E., Wood L., and von der Maase H. European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I. Eur. Urol. 53 (2008) 478-496
18. Krege S., Beyer J., Souchon R., Albers P., Albrecht W., Algaba F., Bamberg M., Bodrogi I., Bokemeyer C., Cavallin-Stahl E., Classen J., Clemm C., Cohn-Cedermark G., Culine S., Daugaard G., De Mulder P.H., De Santis M., de Wit M., de Wit R., Derigs H.G., Dieckmann K.P., Dieing A., Droz J.P., Fenner M., Fizazi K., Flechon A., Fossa S.D., del Muro X.G., Gauler T., Geczi L., Gerl A., Germa-Lluch J.R., Gillessen S., Hartmann J.T., Hartmann M., Heidenreich A., Hoeltl W., Horwich A., Huddart R., Jewett M., Joffe J., Jones W.G., Kisbenedek L., Klepp O., Kliesch S., Koehrmann K.U., Kollmannsberger C., Kuczyk M., Laguna P., Galvis O.L., Loy V., Mason M.D., Mead G.M., Mueller R., Nichols C., Nicolai N., Oliver T., Ondrus D., Oosterhof G.O., Paz-Ares L., Pizzocaro G., Pont J., Pottek T., Powles T., Rick O., Rosti G., Salvioni R., Scheiderbauer J., Schmelz H.U., Schmidberger H., Schmoll H.J., Schrader M., Sedlmayer F., Skakkebaek N.E., Sohaib A., Tjulandin S., Warde P., Weinknecht S., Weissbach L., Wittekind C., Winter E., Wood L., and von der Maase H. European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part II. Eur. Urol. 53 (2008) 497-513
19. Lundin K.B., Giwercman A., Richthoff J., Abrahamsson P.A., and Giwercman Y.L. No association between mutations in the human androgen receptor GGN repeat and inter-sex conditions. Mol. Hum. Reprod. 9 (2003) 375-379
20. Lundin K.B., Giwercman Y.L., Rylander L., Hagmar L., and Giwercman A. Androgen receptor gene GGN repeat length and reproductive characteristics in young Swedish men. Eur. J. Endocrinol. 155 (2006) 347-354
21. Macleod J.E., DeLeo J.A., Hickey W.F., Ahles T.A., Saykin A.J., and Bucci D.J. Cancer chemotherapy impairs contextual but not cue-specific fear memory. Behav. Brain Res. 181 (2007) 168-172
22. Mykletun A., Dahl A.A., Haaland C.F., Bremnes R., Dahl O., Klepp O., Wist E., and Fossa S.D. Side effects and cancer-related stress determine quality of life in long-term survivors of testicular cancer. J. Clin. Oncol. 23 (2005) 3061-3068
23. Nieschlag E., Behre H.M., Bouchard P., Corrales J.J., Jones T.H., Stalla G.K., Webb S.M., and Wu F.C. Testosterone replacement therapy: current trends and future directions. Hum. Reprod. Update 10 (2004) 409-419
24. Nijman J.M., Schraffordt Koops H., Kremer J., and Sleijfer D.T. Gonadal function after surgery and chemotherapy in men with stage II and III nonseminomatous testicular tumors. J. Clin. Oncol. 5 (1987) 651-656
25. T'Sjoen G.G., De Vos S., Goemaere S., Van Pottelbergh I., Dierick M., Van Heeringen C., and Kaufman J.M. Sex steroid level, androgen receptor polymorphism, and depressive symptoms in healthy elderly men. J. Am. Geriatr. Soc. 53 (2005) 636-642
26. Tut T.G., Ghadessy F.J., Trifiro M.A., Pinsky L., and Yong E.L. Long polyglutamine tracts in the androgen receptor are associated with reduced trans-activation, impaired sperm production, and male infertility. J. Clin. Endocrinol. Metab. 82 (1997) 3777-3782
27. Wiechno P., Demkow T., Kubiak K., Sadowska M., and Kaminska J. The quality of life and hormonal disturbances in testicular cancer survivors in Cisplatin era. Eur. Urol. 52 (2007) 1448-1454
28. Willemse P.H., Sleijfer D.T., Sluiter W.J., Schraffordt Koops H., and Doorenbos H. Altered Leydig cell function in patients with testicular cancer: evidence for bilateral testicular defect. Acta Endocrinol. (Copenh.) 102 (1983) 616-624
29. Winters S.J. Diurnal rhythm of testosterone and luteinizing hormone in hypogonadal men. J. Androl. 12 (1991) 185-190
30. Zigmond A.S., and Snaith R.P. The hospital anxiety and depression scale. Acta Psychiatr. Scand. 67 (1983) 361-370